Tim Harrison
Contributor since: 2014
Intra-Cellular Therapies: This Small Cap Biotech Will Not Be Small For Long
This Small Biotech Is About To Take Off
Karyopharm's Selinexor Should Drive Substantial Growth
Zogenix Is On The Precipice Of Substantial Growth - Part 2
Zogenix Is On The Precipice Of Substantial Growth
Corcept: A Profitable Biotech With A Bright Future
Egalet: A Promising Company Currently On Sale
Supernus Pharmaceuticals Offers A Rare Opportunity For Investors
Ford Shares Offer Income, Growth, And Value
Should Gilead Acquire Puma Biotechnology?
Update: Latest Pullback Offers A Great Opportunity In Michael Kors
Gilead Sciences: After The Bloodbath The Stock Is A Strong Buy
Gilead Sciences: First Oncology Drug Strengthens War Chest
Gilead's Value Without Its Hep C Franchise
Amgen Fights To Protect Neupogen's Exclusivity
Michael Kors Offers Strong Growth And Is On Sale
Gilead Sciences: Even More Attractive After Third Quarter Results
Gilead Sciences: Will Warehousing Dampen Q3 Revenues?
Home Depot: Despite A Nice Run, It's Still A Buy
AT&T's Intrinsic Value Implies 10% Upside In Shares
Gilead Sciences: Pricing, Politics And Profits
Gilead Sciences: Ignore Recent Insider Selling
Safe Harbor Equities In A Spooky Market
Gilead Sciences: Hitch Your Wagon To This Biotech Juggernaut Before It Really Takes Off